Watanabe, Junichiro

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 922

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients

Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., et al. (2019) · British Journal of Cancer

Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery

Cited by 147

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

Takahashi, S., Karayama, M., Takahashi, M., Watanabe, J., Minami, H., Yamamoto, N., Kinoshita, I., Lin, C.-C., Im, Y.-H., Achiwa, I., et al. (2021) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism

Cited by 37